Cargando…
FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy
BACKGROUND: The role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in prostate cancer (PCa) has not been well defined yet. Because high-grade PCa tends to exhibit increased glycolytic rate, FDG-PET/CT could be useful in this setting. The aim of this study...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352558/ https://www.ncbi.nlm.nih.gov/pubmed/25889163 http://dx.doi.org/10.1186/s40644-015-0038-0 |
_version_ | 1782360479422742528 |
---|---|
author | Beauregard, Jean-Mathieu Blouin, Annie-Claude Fradet, Vincent Caron, André Fradet, Yves Lemay, Claude Lacombe, Louis Dujardin, Thierry Tiguert, Rabi Rimac, Goran Bouchard, Frédérick Pouliot, Frédéric |
author_facet | Beauregard, Jean-Mathieu Blouin, Annie-Claude Fradet, Vincent Caron, André Fradet, Yves Lemay, Claude Lacombe, Louis Dujardin, Thierry Tiguert, Rabi Rimac, Goran Bouchard, Frédérick Pouliot, Frédéric |
author_sort | Beauregard, Jean-Mathieu |
collection | PubMed |
description | BACKGROUND: The role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in prostate cancer (PCa) has not been well defined yet. Because high-grade PCa tends to exhibit increased glycolytic rate, FDG-PET/CT could be useful in this setting. The aim of this study was to assess the value of FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade PCa at biopsy. METHODS: Fifty-four patients with a Gleason sum ≥8 PCa at biopsy underwent FDG-PET/CT as part of the staging workup. Thirty-nine patients underwent radical prostatectomy (RP) and pelvic lymph node (LN) dissection, 2 underwent LN dissection only, and 13 underwent non-surgical treatments. FDG-PET/CT findings from clinical reports, blinded reading and quantitative analysis were correlated with clinico-pathological characteristics at RP. RESULTS: Suspicious foci of increased FDG uptake were found in the prostate, LNs and bones in 44, 13 and 6% of patients, respectively. Higher clinical stage, post-RP Gleason sum and pattern, and percentage of cancer involvement within the prostate were significantly associated with the presence of intraprostatic FDG uptake (IPFU) (P < 0.05 in all cases). Patients without IPFU who underwent RP were downgraded to Gleason ≤7 in 84.6% of cases, as compared to 30.8% when IPFU was reported (P = 0.003). Qualitative and quantitative IPFU were significantly positively correlated with post-RP Gleason pattern and sum, and pathological T stage. Absence and presence of IPFU were associated with a median 5-year cancer-free survival probability of 70.2 and 26.9% (P = 0.0097), respectively, using the CAPRA-S prognostic tool. CONCLUSION: These results suggest that, among patients with a high-grade PCa at biopsy, FDG-PET/CT could improve pre-treatment prognostic stratification by predicting primary PCa pathological grade and survival probability following RP. |
format | Online Article Text |
id | pubmed-4352558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43525582015-03-09 FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy Beauregard, Jean-Mathieu Blouin, Annie-Claude Fradet, Vincent Caron, André Fradet, Yves Lemay, Claude Lacombe, Louis Dujardin, Thierry Tiguert, Rabi Rimac, Goran Bouchard, Frédérick Pouliot, Frédéric Cancer Imaging Research Article BACKGROUND: The role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in prostate cancer (PCa) has not been well defined yet. Because high-grade PCa tends to exhibit increased glycolytic rate, FDG-PET/CT could be useful in this setting. The aim of this study was to assess the value of FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade PCa at biopsy. METHODS: Fifty-four patients with a Gleason sum ≥8 PCa at biopsy underwent FDG-PET/CT as part of the staging workup. Thirty-nine patients underwent radical prostatectomy (RP) and pelvic lymph node (LN) dissection, 2 underwent LN dissection only, and 13 underwent non-surgical treatments. FDG-PET/CT findings from clinical reports, blinded reading and quantitative analysis were correlated with clinico-pathological characteristics at RP. RESULTS: Suspicious foci of increased FDG uptake were found in the prostate, LNs and bones in 44, 13 and 6% of patients, respectively. Higher clinical stage, post-RP Gleason sum and pattern, and percentage of cancer involvement within the prostate were significantly associated with the presence of intraprostatic FDG uptake (IPFU) (P < 0.05 in all cases). Patients without IPFU who underwent RP were downgraded to Gleason ≤7 in 84.6% of cases, as compared to 30.8% when IPFU was reported (P = 0.003). Qualitative and quantitative IPFU were significantly positively correlated with post-RP Gleason pattern and sum, and pathological T stage. Absence and presence of IPFU were associated with a median 5-year cancer-free survival probability of 70.2 and 26.9% (P = 0.0097), respectively, using the CAPRA-S prognostic tool. CONCLUSION: These results suggest that, among patients with a high-grade PCa at biopsy, FDG-PET/CT could improve pre-treatment prognostic stratification by predicting primary PCa pathological grade and survival probability following RP. BioMed Central 2015-03-03 /pmc/articles/PMC4352558/ /pubmed/25889163 http://dx.doi.org/10.1186/s40644-015-0038-0 Text en © Beauregard et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Beauregard, Jean-Mathieu Blouin, Annie-Claude Fradet, Vincent Caron, André Fradet, Yves Lemay, Claude Lacombe, Louis Dujardin, Thierry Tiguert, Rabi Rimac, Goran Bouchard, Frédérick Pouliot, Frédéric FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy |
title | FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy |
title_full | FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy |
title_fullStr | FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy |
title_full_unstemmed | FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy |
title_short | FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy |
title_sort | fdg-pet/ct for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352558/ https://www.ncbi.nlm.nih.gov/pubmed/25889163 http://dx.doi.org/10.1186/s40644-015-0038-0 |
work_keys_str_mv | AT beauregardjeanmathieu fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy AT blouinannieclaude fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy AT fradetvincent fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy AT caronandre fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy AT fradetyves fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy AT lemayclaude fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy AT lacombelouis fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy AT dujardinthierry fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy AT tiguertrabi fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy AT rimacgoran fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy AT bouchardfrederick fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy AT pouliotfrederic fdgpetctforpreoperativestagingandprognosticstratificationofpatientswithhighgradeprostatecanceratbiopsy |